Cargando…
Drug hypersensitivity in drug-resistant tuberculosis
OBJECTIVE: To evaluate drug resıstant tuberculosis patients who developed drug hypersensitivity to antituberculosis drug. METHODS: This was a retrospective study. The primary aim of the study is to determine the demographic and clinical characteristics of patients who develop drug hypersensitivity i...
Autores principales: | Katran, Zeynep Yegin, Bulut, İsmet, Babalık, Aylin, Keren, Metin, Tepetam, Fatma Merve, Mersin, Selver Seda, Örçen, Cihan, Yakut, Tuğçe, Yavuz, Dilek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213312/ https://www.ncbi.nlm.nih.gov/pubmed/37251814 http://dx.doi.org/10.1016/j.waojou.2023.100778 |
Ejemplares similares
-
Management of type 1 immediate hypersensitivity reactions to antituberculosis drug: succesful desensitization
por: Katran, Zeynep Yegin, et al.
Publicado: (2022) -
Does NSAID exacerbated respiratory disease (N-ERD) accompanying severe asthma affect biological treatment response? Efficacy of omalizumab and mepolizumab in N-ERD
por: Tepetam, Fatma Merve, et al.
Publicado: (2023) -
The phenotypic heterogeneity of obese and nonobese patients with severe asthma and comparison of omalizumab–mepolizumab treatment efficiency in these patients
por: Özden, Şeyma, et al.
Publicado: (2023) -
Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic “Overlap” severe asthma: Biological agent preference in atopic-eosinophilic severe asthma
por: Tepetam, Fatma Merve, et al.
Publicado: (2023) -
Can development of asthma and bronchial hyperreactivity be reduced by subcutaneous immunotherapy in adult patients with allergic rhinitis?
por: TEPETAM, Fatma Merve, et al.
Publicado: (2023)